LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
MENLO PARK, Calif., May 22, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference.
| Event: | Jefferies Global Healthcare Conference |
| Date: | June 7, 2017 |
| Time: | 1:30 – 2:00 p.m. ET |
| Location: | New York, NY |
A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]
